Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

DÉCISION+, a Continuous Professional Development Program to Improve Optimal Drug Prescription : a Feasibility Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00354315
Recruitment Status : Completed
First Posted : July 20, 2006
Last Update Posted : February 16, 2009
Sponsor:
Collaborators:
Fonds de la Recherche en Santé du Québec
Conseil du Médicament du Québec
Information provided by:
CHU de Quebec-Universite Laval

Brief Summary:
The objective of this project is to evaluate the feasibility of a larger randomized trial of the efficacy of DECISION+, a continuous professional development program integrating multiple components, to promote shared decision making concerning drug prescription.

Condition or disease Intervention/treatment Phase
Choice Behavior Behavioral: Continuous medical education (CME) Not Applicable

Detailed Description:

The Conseil du médicament du Québec defines optimal drug use as a "use that maximizes benefits and minimizes risks to population health by taking into account available options, costs and resources as well as patient values and social values". This definition appropriately recognizes the uncertainty surrounding the use of most drugs, i.e. there is often more than one good therapeutic option. The Ottawa Decision Support Framework (ODSF) guides practitioners in assessing decision-making needs in clinical practice, providing support for client decision making, and evaluating the effectiveness of their interventions. DECISION+ is an innovative continuous professional development program for physicians, based on the principles of ODSF and Evidence-Based Medicine. It integrates multiple educational - behavioral change components that aim at promoting optimal shared decision making with respect to drug prescription. The investigators hypothesize that optimal shared decision making should result in optimized prescription behaviors by the physician and optimized drug use by the patient. The objective of this pilot clinical randomized trial of DECISION+ is to evaluate the feasibility of a larger randomized clinical trial, in order to determine the efficacy of the program to promote optimal shared decision making in regards to drug prescription by physicians. This pilot evaluation of the program will focus on one clinical theme: antibiotic prescription for acute respiratory infections (ARI).

The program targets general practitioners and combines three strategies that were proven effective to improve healthcare practices:

  1. Interactive workshops
  2. Reminders of expected behaviors
  3. Feedbacks

Three 180-minute workshops will be held over a six-month period and will include:

  1. Retrieval and critical appraisal of information
  2. Clinical practice guidelines
  3. Acquisition of diagnostic skills
  4. Communication of risks and benefits
  5. Shared decision making skills
  6. Barriers and facilitating factors to optimal shared decision making with respect to drug prescription

Family physicians from four large group practices -the randomization unit- in the province of Québec, Canada will be randomly selected and assigned to one of the following interventions:

  1. Immediate DECISION+ antibiotics/ARI program
  2. 6-month delayed DECISION+ antibiotics/ARI program

The main outcome measure of this pilot trial is to determine the feasibility of implementing the DECISION+ program on a large scale. Feasibility will be based on the proportion of contacted group practices that agree to participate, the proportion of recruited physicians that participate in the workshops, the level of satisfaction about the workshop, and the proportion of missing data in each survey. Secondary outcomes will include measure of decision to use antibiotics, decisional conflict, decisional regret, prescription profile of antibiotics in ARI, script concordance test, physician' reaction to uncertainty and intention to engage in SDM and to use clinical practice guidelines regarding the use of antibiotics in ARI in future clinical encounters..

The investigators hypothesize that shared decision making will translate into an optimized prescription by the physician and will lead to an optimized drug use by the patient. We believe that this project will help to enhance the health of the Quebec citizen by a better drug use by the patient.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 642 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: DÉCISION+, a Continuous Professional Development Program to Improve Optimal Drug Prescription : a Feasibility Study
Study Start Date : September 2006
Actual Primary Completion Date : March 2008
Actual Study Completion Date : March 2008

Arm Intervention/treatment
Experimental: 1
Immediate Continuous medical education (CME)
Behavioral: Continuous medical education (CME)
The intervention will be held over a 6 months period. DECISION+ is a multifaceted intervention program that includes: Interactive workshops (3x180 min), reminders of expected behaviours and feedback.

No Intervention: 2
control, 6 months delay CME intervention



Primary Outcome Measures :
  1. feasibility of a larger RCT aiming at promoting optimal shared decision making in regards to antibiotics prescription by GPs and antibiotics use by patients in acute upper respiratory infections [ Time Frame: two years ]

Secondary Outcome Measures :
  1. decision to use antibiotics [ Time Frame: one year ]
  2. decisional conflict [ Time Frame: one year ]
  3. decisional regret [ Time Frame: one year ]
  4. prescription profile of antibiotics in ARI [ Time Frame: 18 months ]
  5. script concordance test [ Time Frame: one year ]
  6. physician' reactions to uncertainty [ Time Frame: one year ]
  7. Intention to engage in SDM and to use clinical practice guidelines regarding the use of antibiotics in ARI in future clinical encounters [ Time Frame: one year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Physician: Family medicine group practices (Groupe de médicine familiale) of at least 12 members located in one of the two following regions: Québec and Chaudière-Appalaches, and from which at least 6 members have agreed to participate in the study.

Patients : a) Adult or child consulting a participating physician for an acute respiratory infection (ARI) (i.e. otitis media, rhino-sinusitis, pharyngo-laryngitis, or acute bronchitis), b) Adult or child for whom a treatment with an antibiotic is considered by the patient himself (or guardian, if for a child) or by the physician; c) Patient skills in reading, understanding, and writing French (or guardian, if for a child) equivalent to grade 8; d) Patient (or guardian, if for a child) who can give informed consent for his participation in the study. Patient with a condition requiring emergency care and/or transfer to another care unit will be excluded (e.g.: psychiatric condition, cardiac or pulmonary conditions, a major infection).


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00354315


Locations
Layout table for location information
Canada
Centre hospitalier universitaire de Québec, Hôpital Saint-François d'Assise
Quebec, Canada, G1L 3L5
Sponsors and Collaborators
CHU de Quebec-Universite Laval
Fonds de la Recherche en Santé du Québec
Conseil du Médicament du Québec
Investigators
Layout table for investigator information
Principal Investigator: Michel Labrecque, MD CHU de Quebec-Universite Laval
Principal Investigator: France Légaré, MD CHU de Quebec-Universite Laval

Additional Information:
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: France Légaré and Michel Labrecque, Centre hospitalier universitaire de Québec
ClinicalTrials.gov Identifier: NCT00354315     History of Changes
Other Study ID Numbers: CRCHUQ-5-05-12-03
FRSQ-051711
First Posted: July 20, 2006    Key Record Dates
Last Update Posted: February 16, 2009
Last Verified: July 2008

Keywords provided by CHU de Quebec-Universite Laval:
Shared decision making
Optimal drug prescription